Effect of aspirin in fatigue of multiple sclerosis

Comparison of the effect of aspirin and placebo for the treatment of fatigue in multiple sclerosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230802059008N1

Enrollment

Registered

2023-11-11

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: 20 patients are treated with aspirin 325 mg (Produced by Pars Daru Company)daily.The patients are given the necessary training in case of possible side effects rela

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: FSS score>=4 EDSS<=6 Patients with multiple sclerosis (age between18_55)

Exclusion criteria

Exclusion criteria: Depression Hypothyroidism Pregnancy Anemia Thrombocytopenia Hx of GI bleeding ,GI ulcer Asthma Alcohol use MS attack in the last 4weeks that corticosteroid used for treatment Chronic renal disease Chronic pulmonary disease Chronic metabolic disease Chronic heart disease

Design outcomes

Primary

Measure	Time frame
Severity of fatigue. Timepoint: Measuring the intensity of fatigue at the beginning of the study (before the start of the intervention) and 42 days after taking aspirin 325 mg and placebo (at the end of the study - 6 weeks later). Method of measurement: Fatigue severity scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtab Karami

Kashan University of Medical Sciences

Mahtabkarami303@yahoo.com+98 71 3632 1057

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026